Oncotherapy Science
Kawasaki City, Japan· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Japanese biotech developing genome-based molecular-targeted cancer therapies including small molecule inhibitors and cancer vaccines.
Oncology
Technology Platform
Proprietary platform combining laser microbeam microdissection (LMM) for pure cancer cell isolation with a high-sensitivity cDNA microarray system for comprehensive gene expression profiling to identify cancer-specific therapeutic targets.
Opportunities
Opportunities include advancing its novel TOPK and MELK inhibitors into clinical trials, leveraging its genomic platform for new target discovery, and growing its precision medicine diagnostics/services business through its subsidiary CPM.
Risk Factors
Key risks include high preclinical/clinical development failure rates, dependence on key scientific collaborator Professor Nakamura, intense competition in oncology drug development, and potential funding constraints as a public micro-cap biotech.
Competitive Landscape
OTS competes with numerous global oncology biotechs and pharmas; its differentiation lies in its proprietary target discovery platform focused on pure cancer cell genomics and its collaboration with a leading genomics pioneer.